Project Grant R01HL179077
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) aims to elucidate the complex relationship between obstructive sleep apnea (OSA) and cardiovascular disease (CVD). The $1,296,660 award supports a 24-month research project that will employ a "bed to bench" approach integrating clinical, computational, and in vitro techniques. Key objectives include developing and validating a mathematical model to quantify...
- This $782,473 federal Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research to improve understanding of the pathogenesis of sleep apnea using novel imaging techniques during sleep. The project aims to characterize the site and pattern of airway collapse as well as how upper airway anatomy mediates this collapse, which could provide new insights to guide optimal therapies, particularly for patients who cannot tolerate...
- This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $818,279 to Brigham & Women's Hospital, a subsidiary of Partners Healthcare System, to conduct research on improving the subtyping and characterization of obstructive sleep apnea (OSA). The project will leverage data from existing research cohorts and a clinical biobank to quantify the reproducibility of OSA severity markers and derive physiologically...
- This Project Grant award, funded by the National Heart, Lung, and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837), aims to study the impact of positive airway pressure (PAP) therapy on myocardial blood flow in adults with obstructive sleep apnea (OSA) at high risk of cardiovascular disease. The $173,556 award to Yale University will recruit 60 individuals with moderate PAP-naive OSA to test the hypotheses that OSA-specific measures of hypoxia and autonomic...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $1,415,112 project grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Nebraska Medical Center (UNMC) to evaluate a telehealth-delivered adaptive intervention for improving continuous positive airway pressure (CPAP) therapy adherence and health outcomes in adults with obstructive sleep apnea (OSA). The project aims to: 1) compare effects of motivational enhancement, device support, and...
- This federal Project Grant award, provided by the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research), supports a comprehensive sleep neuroimaging study to investigate the role of local sleep disturbance in obesity risk. The $568,125 award to Brigham Young University, with a period of performance from September 2025 to August 2028, will utilize advanced functional neuroimaging and polysomnographic methods to elucidate the underlying mechanisms linking poor...
- The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), awarded a $816,472 project grant to the Icahn School of Medicine at Mount Sinai (ISMMS). The grant, awarded on August 1, 2025 and set to conclude on May 31, 2029, aims to enhance cardiovascular risk prediction and treatment response in obstructive sleep apnea (OSA) patients using advanced AI-based transformer models and multi-modal sleep data. The project will...
- This federal Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $248,088 to the University of California, San Diego (UCSD) to conduct a mechanistic study on cardiovascular outcomes in patients with comorbid obstructive sleep apnea (OSA) and chronic obstructive pulmonary disease (COPD), referred to as overlap syndrome (OVS). The central hypothesis is that poor cardiovascular outcomes in OVS, compared to COPD or OSA alone,...
- This Project Grant award of $807,067.00 from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) will support a study to pioneer the quantitative documentation of human respiratory kinematic profiles. The study aims to address a critical gap in contemporary physiological monitoring - the inability to quantify labored breathing, which contains vital prognostic information not captured by conventional monitoring. Building on a recent innovation called ARK...
- This federal Project Grant award, valued at $678,710 and awarded on June 15, 2025, was provided by the National Heart, Lung, and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837). The award supports the development and validation of a novel multi-sensor machine learning approach to precision sleep tracking for nightshift workers. The project aims to leverage wearable devices, environmental sensors, and machine learning algorithms to accurately detect sleep patterns...
This $764,853 Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to Yale University supports research to understand the role of arousal threshold (ARTH) as a determinant of adherence and outcomes for continuous positive airway pressure (CPAP) therapy in obstructive sleep apnea (OSA). The research aims to validate ARTH as a biomarker to guide precision OSA therapy, as poor adherence and inconsistent impacts on neurocognitive and cardiovascular outcomes limit the effectiveness of CPAP, which is the primary OSA treatment. The award, with a performance period from August 2025 to May 2030, will fund a research project to prospectively evaluate how ARTH impacts CPAP adherence and its neurocognitive and cardiovascular benefits.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $764.9k | 8/7/25 |